Insights

Synthetic biology remains nascent, yet full of promise. The idea of using rational engineering approaches to design biology has the potential to solve some of humanity’s biggest challenges, such as securing food supplies...

Diagnosing cancer early to treat it more effectively is vital. Here, Josh Gibson, senior physicist at Cambridge Consultants, unveils a potentially life-saving breakthrough in the field of liquid biopsy that’s been hailed by a leading innovation award jury…

The past year has seen an unprecedented acceleration of innovation in the diagnostics space. Reflecting on the virtual themes and debates at Molecular Med Tri-Con 2021, Head of Life Sciences Symon Cotton says that the speed of tests and vaccines coming to market is not having an adverse effect on quality. Medical developments can be safely delivered to quicker timescales...

Symon Cotton, Head of Life Sciences at Cambridge Consultants, attended this year’s Society for Laboratory Automation and Screening conference, SLAS2021. Even in virtual form, the speakers dazzled with fresh and exciting ideas for the future of patient treatments.

The rapid, at home COVID-19 antigen test from digital diagnostics company Ellume features core technology from Cambridge Consultants. Read how this FDA approved test is set to be a game-changer in the global pandemic.

We are delighted to report a significant step forward as we grow our bioinnovation capability as we have received our licence from the UK Human Tissue Authority to store human tissue for research purposes. This opens the way to future development in cell therapies and regenerative medicine. 

Symon Cotton explores the use of pooled testing techniques for deploying mass Covid testing.  

James Hallinan's takeaway from SynBioBeta 2020: Synbio is growing up and getting ever more relevant to the everyday. 

This paper highlights macro and micro factors affecting oncology and proposes a partnership-driven framework to catalyze innovation for oncology-focused biopharma – as well as the role that select high-impact technologies will have on the on the entire value-chain of cancer research and care delivery. 

With a constant stream of good news about potential COVID-19 vaccines, we reflect on traditional viral vaccine manufacturing processes and how we apply what we’re learning during this pandemic to legacy techniques.

The UK biotechnology scene is buzzing with debate right now, with critical themes like green growth and sustainability really coming to the fore. The pandemic has thrust science and scientists into the spotlight like never before – and each of us has a responsibility to contribute to the sort of response that will help create a more resilient world.  

Richard Hammond presents a seminar on Bioinnovation from Innovation Day UK 2019.